



**INTERNATIONAL
SOCIETY FOR
STEM CELL
RESEARCH**

BOARD OF DIRECTORS

President

Hideyuki Okano, MD, PhD
Keio University, Japan

President Elect

Lorenz Studer, MD
Memorial Sloan Kettering Cancer Center, USA

Vice President

Fiona Doetsch, PhD
Biozentrum at the University of Basel, Switzerland

Treasurer

Lee Rubin, PhD
Harvard University Department of Stem Cell and Regenerative Biology, USA

Clerk

Megan Munsie, PhD
University of Melbourne and Murdoch Children's Research Institute, Australia

Immediate Past President

Valentina Greco, PhD
Yale Stem Cell Center, USA

Directors

Jacqueline Barry, PhD
Cell and Gene Therapy Catapult, UK

Melissa K. Carpenter, PhD
Carpenter Consulting Corporation, USA

Shuibing Chen, PhD
Weill Cornell Medicine, USA

Michele De Luca, MD
University of Modena & Reggio Emilia, Italy

Lijian Hui, PhD
Shanghai Institute of Biochemistry and Cellular Biology, Chinese Academy of Sciences, China

Jürgen Knoblich, PhD
Institute of Molecular Biotechnology & Medical University of Vienna, Austria

Tennelle E. Ludwig, PhD
WiCell, USA

Kathy Niakan, PhD
University of Cambridge, UK

Malin Parmar, PhD
Lund University, Sweden

Lygia da Veiga Pereira, PhD
Universidade de São Paulo, Brazil

Thomas A. Rando, MD, PhD
University of California, Los Angeles, USA

Mitunori Saitou, MD, PhD
Kyoto University, Japan

Clive Svendsen, PhD
Cedars-Sinai Regenerative Medicine Institute, USA

Wei Xie, PhD
Tsinghua University, China

Peter Zandstra, PhD, FRSC, PEng
University of British Columbia, Canada

Kenneth S. Zaret, PhD
University of Pennsylvania School of Medicine, USA

Amander T. Clark, PhD, Ex Officio
University of California, Los Angeles, USA

Janet Rossant, CC, PhD, Ex Officio
Stem Cell Reports Editor-in-Chief and The Gairdner Foundation, Canada

Leonard I. Zon, MD, Ex Officio
Boston Children's Hospital, USA

Keith Alm, MBA
Chief Executive Officer

Dr. Kiran Kumar Karlapu
Director (Drugs Regulation)
Ministry of Health and Family Welfare
Government of India
Room No. 407, A Wing
Nirman Bhavan
New Delhi, India 110011

14 November 2025

Dear Director Karlapu,

On behalf of the International Society for Stem Cell Research (ISSCR), I write to share our comments regarding the draft amendments to the Drugs Rules, 1945, to strengthen the Government of India's regulatory framework for cell- and stem cell-derived products. The ISSCR is the leading professional organization of stem cell scientists, representing nearly 5,000 members around the world, including in India. Our members are scientists, clinicians, ethicists, and educators dedicated to the responsible advancement of stem cell research and its translation to the clinic. The ISSCR commends the Government of India for taking steps to strengthen its regulatory framework for advanced therapeutic products, including cell- and stem cell-derived products.

As stem cell research and its translation to the clinic advances, ensuring a regulatory framework that encourages responsible innovation while safeguarding patient well-being is essential. The Government of India should maintain and enforce rigorous review pathways to ensure that stem cell-based products conform to the highest standards of evidence-based medicine. Further, these products should be subjected to appropriate manufacturing regulations to ensure their quality and safety.

Without such guardrails, patients face significant health and financial risks from unproven cell- and stem cell-derived products. Severe adverse events, including lifelong disability and death, arising from the administration of these products have been documented [across the world](#), including in India. The Indian Council of Medical Research has identified the need for evidence-based use of cell- and stem cell-derived products, [noting in a recent report](#) that "Several instances of public exploitation and grievances from members of the public have been received by the ICMR and other government agencies" regarding unproven cell and stem cell-derived products, with demands for action to curb such practices.

To that end, the proposed Drugs Rules Amendments, 2025, advances regulatory clarity for cell- and stem cell-derived products in India and would help to promote the rigorous regulatory reviews necessary to protect patients. Again, we commend the Government of India for taking these steps and would welcome the opportunity for further dialogue.

Excellence in stem cell science and applications to human health.

isscr.org | isscr@isscr.org | +1 (224) 592-5700
630 Davis St, Suite 200, Evanston, IL 60201 USA



INTERNATIONAL
SOCIETY FOR
STEM CELL
RESEARCH

Respectfully,

Hideyuki Okano, MD, PhD
President
ISSCR

Excellence in stem cell science and applications to human health.

isscr.org | isscr@isscr.org | +1 (224) 592-5700
630 Davis St, Suite 200, Evanston, IL 60201 USA